These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 24165429)

  • 21. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2.
    Taylor AJ; Zhu D; Sullenberger LE; Lee HJ; Lee JK; Grace KA
    Vasc Health Risk Manag; 2007; 3(1):159-64. PubMed ID: 17583186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
    Capuzzi DM; Guyton JR; Morgan JM; Goldberg AC; Kreisberg RA; Brusco OA; Brody J
    Am J Cardiol; 1998 Dec; 82(12A):74U-81U; discussion 85U-86U. PubMed ID: 9915666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemia.
    Jelesoff NE; Ballantyne CM; Xydakis AM; Chiou P; Jones PH; Guyton JR
    Endocr Pract; 2006; 12(2):159-64. PubMed ID: 16690463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes.
    Kane MP; Hamilton RA; Addesse E; Busch RS; Bakst G
    Pharmacotherapy; 2001 Dec; 21(12):1473-8. PubMed ID: 11765300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study.
    Nicholls SJ; Tuzcu EM; Wolski K; Bayturan O; Lavoie A; Uno K; Kupfer S; Perez A; Nesto R; Nissen SE
    J Am Coll Cardiol; 2011 Jan; 57(2):153-9. PubMed ID: 21211686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
    Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
    Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
    Herz M; Johns D; Reviriego J; Grossman LD; Godin C; Duran S; Hawkins F; Lochnan H; Escobar-Jiménez F; Hardin PA; Konkoy CS; Tan MH
    Clin Ther; 2003 Apr; 25(4):1074-95. PubMed ID: 12809958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.
    Göke B;
    Treat Endocrinol; 2002; 1(5):329-36. PubMed ID: 15832486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
    Morgan JM; Capuzzi DM; Guyton JR
    Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial.
    AIM-HIGH Investigators
    Am Heart J; 2011 Mar; 161(3):538-43. PubMed ID: 21392609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
    Aljabri K; Kozak SE; Thompson DM
    Am J Med; 2004 Feb; 116(4):230-5. PubMed ID: 14969650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
    Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
    Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pioglitazone decreases plasma cholesteryl ester transfer protein mass, associated with a decrease in hepatic triglyceride content, in patients with type 2 diabetes.
    Jonker JT; Wang Y; de Haan W; Diamant M; Rijzewijk LJ; van der Meer RW; Lamb HJ; Tamsma JT; de Roos A; Romijn JA; Rensen PC; Smit JW
    Diabetes Care; 2010 Jul; 33(7):1625-8. PubMed ID: 20150294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
    Kaku K
    Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups.
    Bays H; Shah A; Dong Q; McCrary Sisk C; Maccubbin D
    Int J Clin Pract; 2011 Apr; 65(4):436-45. PubMed ID: 21401833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy.
    Derosa G; Tritto I; Romano D; D'Angelo A; Catena G; Maffioli P
    J Clin Pharmacol; 2019 Oct; 59(10):1391-1399. PubMed ID: 31131461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
    Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
    Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.